Description
Vinpotropil Pharmacodynamics
Vinpotropil® is a combination drug. It has properties typical for a drug that improves cerebral blood flow (Vinpocetine) and for a nootropic (Piracetam).
As a means of improving cerebral blood flow:
Improves brain metabolism by increasing glucose and oxygen uptake by brain tissue. Increases resistance of neurons to hypoxia; enhances glucose transport to the brain through the blood-brain barrier; transfers glucose breakdown to a more energy-saving aerobic pathway; selectively blocks Ca2+-dependent phosphodiesterase; increases levels of adenosine monophosphate (AMP), cyclic guanosine monophosphate (cGMP) and adenosine triphosphate (ATP) of the brain. Enhances metabolism of brain noradrenaline and serotonin; stimulates the ascending branch of the noradrenergic system, has an antioxidant effect. Reduces platelet aggregation and increased blood viscosity; increases erythrocyte elasticity and blocks erythrocyte utilization of adenosine; helps increase erythrocyte oxygen output. Increases cerebral blood flow; reduces cerebral vascular resistance without significant changes in systemic blood flow. Does not have the effect of “stealing” and increases blood supply, especially in ischemic areas of the brain. It penetrates through the placental barrier.
As a nootropic agent:
Has a positive effect on brain metabolic processes, slightly increases the concentration of ATP in the brain, enhances the synthesis of ribonucleic acid and phospholipids, stimulates glycolytic processes, increases glucose utilization; improves integrative activity of the brain, promotes memory consolidation, facilitates learning; changes the speed of excitation spread in the brain, improves microcirculation without having a vasodilatory effect, inhibits aggregation of activated platelets The effect develops gradually.
It has a pronounced effect on symptoms of initial manifestations of cognitive disorders of cerebral-vascular genesis in elderly and senile patients. It is recommended in psychogeriatric practice.
Indications
Insufficiency of cerebral circulation (recovery period of ischemic and hemorrhagic stroke), encephalopathies of various genesis, including alcoholism; parkinsonism of vascular genesis, intoxications, brain injuries and other central nervous system diseases accompanied by decreased intellectual and mental functions; psychoorganic syndrome with predominant symptoms of asthenia and adynamy, asthenic syndrome; labyrinthopathy, Meniere’s syndrome; prevention of migraine and kinetosis.
Contraindications
Hypersensitivity, pregnancy, lactation, marked heart rhythm disorders, coronary heart disease (severe course), acute stage of hemorrhagic stroke, renal and/or hepatic insufficiency, children under 18 years of age (due to insufficient data).
Patients with rare hereditary diseases such as galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take the drug.
Caution:
Impaired hemostasis, severe bleeding, benign hyperbilirubinemia (including Gilbert syndrome), viral hepatitis, alcoholic liver damage, alcoholism, glucose-6-phosphate dehydrogenase deficiency, epilepsy, advanced age.
Dosage and administration method
- The course of treatment and dosage is determined by the attending physician.
For patients 18 years and older: orally, regardless of meals, 1 tablet 2 – 3 times a day with plenty of water. The last dose four hours before bedtime. Duration of treatment is from 2-3 weeks to 2-6 months. Before withdrawal of the drug, it is recommended to reduce the dose gradually (it is possible to use Vinpotropil® in another dosage form: capsules containing 5 mg of Vinpocetine and 400 mg of Piracetam).
